Publisher: Consultant Live

At RAD2026, Lieberman notes advances in immunology and systemic therapies that are reshaping the link between dermatology and allergy/immunology.

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

February 2026 brought several notable developments across allergy and immunology, spanning regulatory decisions, updated clinical guidance, and emerging research presented at the 2026 American Academy of Allergy, Asthma, & Immunology annual meeting in Philadelphia from February 27 to March 2.

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes. Jay Lieberman, MD, is an associate professor from the College of Medicine in Memphis, department of pediatrics, and division of pediatric pulmonology at the University of Tennessee Health Science Center.

Investigative topical immunomodulator ILYX-002 has proven its efficacy in treating moderate-to-severe dry eye disease (DED) by achieving its primary endpoint of total conjunctival staining in the recent ILYX-002-201 phase 2 trial.

At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, the HCPLive editorial team sat down with Tejesh Patel, MD/MBBS, about his portion of the session at RAD titled ‘Dose Flexibility in Adult Atopic Dermatitis.’